Inhibiting PARP2 in siPFKFB4 100 nM, siHMOX1, and DOX alone, and its downregulation in siPFKFB4 100 nM and DOX, led to suppressed cell proliferation and improved chemotherapy potency against aggressive tumor cells. The gene discussed is PARP2; the disease is neoplasm.